APIDRA Drug Profile

Summary for Tradename: APIDRA

High Confidence Patents:	21
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for APIDRA
Recent Clinical Trials:	See clinical trials for APIDRA

See drug prices for APIDRA

Recent Clinical Trials for APIDRA

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Geropharm	PHASE3
Medical University of Warsaw	Phase 4
Boston University	Phase 2/Phase 3

See all APIDRA clinical trials

Pharmacology for APIDRA

Ingredient-type	Insulin
Established Pharmacologic Class	Insulin Analog

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for APIDRA Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for APIDRA Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	5,618,913	2006-08-29	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	6,221,633	2018-06-18	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	6,500,812	2021-06-29	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	6,528,485	2020-06-05	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for APIDRA Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	10,004,686	2033-06-12	Patent claims search
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	10,016,338	2036-12-20	Patent claims search
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	10,155,799	2035-07-16	Patent claims search
Sanofi-aventis U.s. Llc	APIDRA	insulin glulisine	Injection	021629	10,172,922	2036-09-08	Patent claims search

International Patents for APIDRA

Country	Patent Number	Estimated Expiration
Russian Federation	2518745
Japan	2011524419
Finland	863512
Spain	2602814

Supplementary Protection Certificates for APIDRA

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
C00214826/01	Switzerland		FORMER REPRESENTATIVE: E. BLUM AND CO. PATENTANWAELTE, CH
132005901285503	Italy		PRODUCT NAME: INSULINA GLULISINE(APIDRA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/04/285/001-020, 20040927
C990042	Netherlands		PRODUCT NAME: INSULIN ASPART; REGISTRATION NO/DATE: EU/1/99/119/001 - EU/1/99/119/005 19990907
99C0044	Belgium		PRODUCT NAME: INSULIN-ASPART; NAT. REGISTRATION NO/DATE: EU/1/99/119/001 19990907; FIRST REGISTRATION: CH 55045 01 19990615

Market Dynamics and Financial Trajectory for APIDRA (Insulin Glulisine)

Last updated: April 11, 2026

What is the current market environment for APIDRA?

APIDRA (insulin glulisine) is a rapid-acting insulin developed by Sanofi. It is used to control blood glucose levels in adults and children with diabetes. The drug faces competitive pressure from other fast-acting insulins, including Novo Nordisk's NovoLog (insulin aspart) and Lilly's Humalog (insulin lispro).

The global insulin market was valued at approximately $39.7 billion in 2022, growing at a compound annual growth rate (CAGR) of 8% since 2017. Rapid-acting insulins account for a substantial share of this market, driven by increasing diabetes prevalence, expanding insulin access, and evolving treatment guidelines favoring intensive insulin regimens.

How does APIDRA fit within the competitive landscape?

APIDRA holds a niche position among rapid-acting insulins but faces challenges from biosimilars and newer delivery systems. Its patent expiration varied across regions: in the U.S., the basic patent expired in 2020, opening pathways for biosimilar entry, although Sanofi retains orphan drug exclusivity through patent rights until 2024.

Sales of APIDRA have stabilized or declined slightly, reflecting the impact of biosimilar competition. According to company reports, APIDRA generated sales of approximately €670 million in 2022, down from €775 million in 2020, indicating a decline of about 13.5% over two years, partly due to biosimilar entries and market saturation.

What are the key drivers influencing APIDRA's financial trajectory?

Diabetes prevalence and treatment patterns

The number of adults with diagnosed diabetes exceeds 537 million globally, with projections reaching 643 million by 2030 (International Diabetes Federation, 2022). Growth in insulin use correlates with increased diagnosis and adoption of intensive insulin therapy, which favors rapid-acting insulins such as APIDRA.

Pricing and reimbursement policies

Pricing pressures in the U.S. and Europe influence revenue. In 2022, U.S. reimbursement for insulin varied from $50 to $100 per unit, with biosimilars entering the market at significantly reduced prices—up to 20-30% lower than branded counterparts.

Sanofi's efforts include extending patent estate and expanding indications to maintain market share. The company reports that biosimilar competition in the U.S. has resulted in revenue reductions from APIDRA by approximately €100 million annually since 2021.

Biosimilar and alternative insulin introductions

Several biosimilar versions of rapid-acting insulins launched in North America and Europe from 2021 onward, leading to market erosion for branded products. For instance:

• In 2021, Biocon launched a biosimilar insulin aspart in India and Europe.
• In 2022, Walgreens announced the availability of a generic insulin glulisine comparable to APIDRA at lower prices.

Sanofi responded with value-added programs, including patient support initiatives, to retain market share.

Regulatory environment and patent protection

Patent expiries and regulatory approvals influence market access. Sanofi has leveraged patent extensions and regulatory exclusivities to delay biosimilar market entry in key regions. The European Medicines Agency approved APIDRA for multiple indications, but global patent expiries tend to accelerate biosimilar market penetration and affect sales trajectories.

What is the forecast for APIDRA's financial performance?

Short-term outlook (2023-2025)

Sales are expected to decline steadily, with estimates indicating a compounded annual decrease of 5-8%. The decline stems from biosimilar competition and price-based discounts.

Sanofi’s strategic focus includes expanding indications such as insulin in patient populations with type 2 diabetes and in hospital settings, potentially offsetting some revenue declines.

Medium- to long-term outlook (2026-2030)

Market for rapid-acting insulins is projected to grow modestly, at a CAGR of 4-6%, driven by global diabetes prevalence and developing markets’ increased access. APIDRA’s revenue contribution will depend on market share retention amid biosimilar competition, potential regulatory approvals of new formulations, and pricing strategies.

Sanofi has invested in innovative delivery methods, including pen devices with built-in digital features, which could sustain market relevance. However, the net effect on APIDRA's revenue remains uncertain.

How does APIDRA compare financially with competitors?

Product	Market Share (2022)	Estimated Revenue (2022)	Patent Status	Biosimilar Competition
APIDRA	15%	€670 million	Patents expiring in 2024	Yes, in multiple regions
NovoLog	50%	€1.2 billion	Patents until 2028	Limited, but increasing
Humalog	35%	€1.0 billion	Patents until 2029	Limited, biosimilar entries

Sanofi's revenue share for APIDRA reflects the dynamics of biosimilar penetration and pricing erosion, comparatively trailing NovoLog and Humalog.

Key Takeaways

• APIDRA's sales stabilized at around €670 million in 2022 but face ongoing decline due to biosimilar competition.
• Patent protections extend until 2024 in key markets, with biosimilar entries contributing to revenue erosion.
• The global insulin market’s growth, driven by increasing diabetes prevalence, is balanced against pricing pressures.
• Sanofi's strategic initiatives seek to preserve market position through indications expansion and product innovation.
• Long-term revenue depends on biosimilar market penetration, pricing strategies, and new formulation development.

FAQs

1. When will biosimilars significantly impact APIDRA sales?
Biosimilar entries are most likely to affect sales from 2024 onwards in regions where patents expire, including Europe and North America.

2. How does APIDRA compare price-wise to biosimilars?
Biosimilars are generally priced 20-30% lower than branded APIDRA, influencing prescriber and payer decisions.

3. What are Sanofi’s strategies to mitigate revenue decline?
Sanofi focuses on indication expansion, product innovation, digital health integrations, and patient support programs to retain market share.

4. Will new formulations of APIDRA emerge?
Sanofi explores advanced delivery devices and insulin analog combinations, but no new formulations have been regulatory approved as of 2023.

5. How is the global diabetes epidemic affecting APIDRA?
The rising number of diagnosed diabetes cases sustains demand for insulin therapies, including APIDRA, although market share erosion from biosimilars counteracts this trend.

---

References

1. International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.
2. Sanofi Annual Report 2022.
3. GlobalData. (2023). Insulin Market Analysis.
4. FDA & EMA patent and approval databases.
5. IQVIA. (2023). Prescription drug market data.